1. Home
  2. ARTL vs PRFX Comparison

ARTL vs PRFX Comparison

Compare ARTL & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTL
  • PRFX
  • Stock Information
  • Founded
  • ARTL 2011
  • PRFX 2007
  • Country
  • ARTL United States
  • PRFX Israel
  • Employees
  • ARTL N/A
  • PRFX N/A
  • Industry
  • ARTL Biotechnology: Pharmaceutical Preparations
  • PRFX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARTL Health Care
  • PRFX Health Care
  • Exchange
  • ARTL Nasdaq
  • PRFX Nasdaq
  • Market Cap
  • ARTL 3.1M
  • PRFX 2.8M
  • IPO Year
  • ARTL N/A
  • PRFX 2020
  • Fundamental
  • Price
  • ARTL $5.31
  • PRFX $1.42
  • Analyst Decision
  • ARTL Buy
  • PRFX Hold
  • Analyst Count
  • ARTL 2
  • PRFX 1
  • Target Price
  • ARTL $30.00
  • PRFX N/A
  • AVG Volume (30 Days)
  • ARTL 117.0K
  • PRFX 8.8M
  • Earning Date
  • ARTL 11-11-2025
  • PRFX 09-23-2025
  • Dividend Yield
  • ARTL N/A
  • PRFX N/A
  • EPS Growth
  • ARTL N/A
  • PRFX N/A
  • EPS
  • ARTL N/A
  • PRFX N/A
  • Revenue
  • ARTL N/A
  • PRFX N/A
  • Revenue This Year
  • ARTL N/A
  • PRFX N/A
  • Revenue Next Year
  • ARTL N/A
  • PRFX N/A
  • P/E Ratio
  • ARTL N/A
  • PRFX N/A
  • Revenue Growth
  • ARTL N/A
  • PRFX N/A
  • 52 Week Low
  • ARTL $4.20
  • PRFX $1.25
  • 52 Week High
  • ARTL $28.60
  • PRFX $16.63
  • Technical
  • Relative Strength Index (RSI)
  • ARTL 31.35
  • PRFX 47.44
  • Support Level
  • ARTL $4.60
  • PRFX $1.32
  • Resistance Level
  • ARTL $4.70
  • PRFX $1.47
  • Average True Range (ATR)
  • ARTL 0.56
  • PRFX 0.13
  • MACD
  • ARTL -0.24
  • PRFX -0.02
  • Stochastic Oscillator
  • ARTL 20.94
  • PRFX 16.67

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About PRFX PainReform Ltd.

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.

Share on Social Networks: